Izhak, L, G. Wildbaum,W. Uri, Y. Shaked, J. Alami, D. Dumont, A. Stein, and N. Karin. 2010. Predominant expression of CCL2 at the tumor site of prostate cancer patients directs a selective loss of immunological tolerance to CCL2 that could be amplified in a beneficial manner. J. Immunol. 184: 1092–1101.

The seventh author's name was omitted from the article. In addition, the third author's name was published incorrectly. The corrected author and affiliation lines are shown below.

Liat Izhak,* Gizi Wildbaum,* Uri Weinberg,* Yuval Shaked, Jennifer Alami, Daniel Dumont, Boris Friedman,§ Avi Stein,§ and Nathan Karin*

*Department of Immunology and Department of Pharmacology, the Ruth and Bruce Rappaport Faculty of Medicine, Rappaport Family Institute for Research in the Medical Sciences, Technion-Institute of Technology; §Department of Urology, Carmel Medical Center and the Ruth and Bruce Rappaport Faculty of Medicine, Haifa, Israel; and Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada